IP Library Granted Patent US 6,887,484
Granted Patent B2
US 6,887,484 · App. 10/209,802 · Granted May 3, 2005

Vaccine composition containing a promoter peptide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,887,484
App. No.
10/209,802
Granted
May 3, 2005
Kind
B2
Abstract

A vaccine having a good vaccination effect, which comprises an antigen; a peptide selected from the group consisting of a peptide having the amino acid sequence of SEQ ID NO: 1, a peptide having the amino acid sequence of SEQ ID NO: 2, and a peptide derived from a peptide having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2; and an immune activator.

Claims (11)

1. A vaccine composition comprising: a specific antigen, wherein an amount of said specific antigen causes an immune response; a peptide selected from the group consisting of a peptide having the amino acid sequence of SEQ ID NO: 1, a peptide having the amino acid sequence of SEQ ID NO: 2, and a peptide derived from a peptide having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2; and an immune activator, in a physiologically acceptable carrier.

2. The vaccine composition of claim 1 , wherein the antigen is a viral protein.

3. The vaccine composition of claim 1 , wherein said antigen is capable of eliciting an immune response against viral hepatitis, influenza, diphtheria, tetanus, pertussis, measles, mumps, rubella, polio, pneumococcus, herpes, respiratory syncytial virus, haemophilus influenza type b, varicella-zoster virus, or rabies.

4. The vaccine composition of claim 1 , wherein the antigen is a recombinant protein.

5. The vaccine composition of claim 1 , wherein the antigen is a recombinant viral protein.

6. The vaccine composition of claim 1 , wherein the antigen is an HCV protein.

7. The vaccine composition of claim 1 , wherein the antigen is an HCV E2 protein.

8. The vaccine composition of claim 1 , wherein the antigen is a recombinant HCV E2 protein.

9. A vaccine composition comprising: an HCV E2 protein; a peptide selected from the group consisting of a peptide having the amino acid sequence of SEQ ID NO: 1, peptide having the amino acid sequence of SEQ ID NO: 2, and a peptide derived from a peptide having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2; and an immune activator, in a physiologically acceptable carrier.

10. The vaccine composition of claim 1 , wherein the amount of the peptide ranges from 0.001 to 1 wt % based on the total weight of the vaccine.

11. The vaccine composition of claim 1 , wherein the immune activator is aluminum hydroxide (alum), Freund's adjuvant, or a mixture thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2023
From: POSCO HOLDINGS INC.; POHANG UNIVERSITY OF SCIENCE & TECHNOLOGY
To: POSCO CO., LTD; POHANG UNIVERSITY OF SCIENCE & TECHNOLOGY
Reel/Frame 063212/0013 →
CHANGE OF NAME Recorded Sep 28, 2022
From: POSCO
To: POSCO HOLDINGS INC.
Reel/Frame 061562/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2002
From: BAE, YOE-SIK; KIM, YOUN-DONG; SEO, YOU-SUK; SUNG, YOUNG-CHUL; SUH, PANN-GHILL; RYU, SUNG-HO; LEE, TAEHOON
To: POSCO; POHANG UNIVERSITY OF SCIENCE & TECHNOLOGY
Reel/Frame 013172/0072 →